Hormones for Genetic Diseases: 60.0% of denials overturned
In 15 California IMR decisions from 2008 to 2025, reviewers overturned 9 (60.0%). In the last five years: 42.9% of 7. 15 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 0.0% |
| 2023 | 1 | 100.0% |
| 2024 | 1 | 0.0% |
| 2025 | 4 | 50.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 4 | 75.0% | 60.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Omnitrope. In this case, the patient has been verifiably diagnosed with Prader-Willi Syndrome (PWS) by methylation assay. Overall, the utilization of GH therapy in the form of Omnitrope is medically appropriate and recommended in this clinical setting. As such, the requested growth hormone (GH), Omnitrope, is medically …”
“Nature of Statutory Criteria/Case Summary: A patient’s parent has requested authorization and coverage for Genotropin five milligram cartridge. The U.S. Food and Drug Administration (FDA) approves the use of daily somatropin therapy for the treatment of Prader-Willi syndrome, noting that it should be considered in conjunction with dietary, environmental, and lifestyle interventions. Upon molecular confirmation of Prader-Willi syndrome, somatropin should …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Nutropin AQ NuSpin. The U.S. Food and Drug Administration (FDA) has approved daily somatotropin for the treatment of short stature in patients with Turner syndrome or short stature homeobox containing (SHOX) gene deficiency. Early initiation of somatotropin therapy before …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for name brand medication, Emflaza. Currently, there is a lack of published data clinically differentiating Emflaza and generic deflazacort. The generic version of deflazacort oral suspension has been approved by the U.S. Food and Drug Administration (FDA) for Becker muscular dystrophy (BMD). FDA-approved generic medications …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Hormones denials for Genetic Diseases overturned?
In 15 California IMR decisions from 2008 to 2025, reviewers overturned 9 (60.0%). In the last five years: 42.9% of 7. 15 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.